Active Ingredient(s):Umeclidinium Bromide FDA Approved: * April 30, 2014 Pharm Company: *GLAXO GRP ENGLAND Category:Anticholinergic
Umeclidinium bromide (trade name Incruse Ellipta) is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol) and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.
It is on the World Health Organization...
* May have multiple approval dates, manufacturers, or labelers. 1 Discussion